Better Stock: AbbVie (ABBV) vs. Eli Lilly (LLY)
If AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) stocks were in a horse race in 2017, Lilly would have been ahead for most of the first half of the race. Over the summer, AbbVie would have pulled ahead by a nose. But by September, Lilly would have fallen well behind, with AbbVie kicking dust in its face. As the year draws to a close, AbbVie stock is up more than 55%, while Lilly stock is up close to 17%.
But Dec. 31 isn't the finish line for investors. The race is only warming up. Which of these two big pharma stocks is the better choice over the long run? Here's how AbbVie and Eli Lilly compare.
Image source: Getty Images.
Source: Fool.com
AbbVie Inc. Aktie
217,60 €
0,60 %
Die Aktie ist derzeit ein absoluter Favorit unserer Community mit 46 Buy-Einschätzungen und keiner einzigen Sell-Einschätzung.
Ein leicht positives Kursziel von 230 € für AbbVie Inc. gegenüber dem aktuellen Kurs von 217.6 € wird gesehen.
